# Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

> clinical trial · VERIFIED · 2026-08-20

Status: NOT_YET_RECRUITING · Sponsor: Genmab · Condition: Colorectal Cancer

- Company: Genmab
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07775287

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.